Insilico Medicine Hong Kong Limited
Clinical trials sponsored by Insilico Medicine Hong Kong Limited, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could an AI-Designed pill take on Hard-to-Treat cancers? Results expected Nov 2026 (estimated)
- New drug ISM8969 enters first human safety tests Results expected Jan 2027 (estimated)
- New pill aims to tame ulcerative colitis Flare-Ups Results expected Aug 2027 (estimated)
- New pill shows promise in early trial for tough cancers Results expected Aug 2027 (estimated)
-
AI-Designed drug targets scarred lungs in major trial
Disease control Recruiting nowThis phase 3 trial tests whether the oral drug rentosertib (INS018_055) can slow lung function decline in adults with idiopathic pulmonary fibrosis (IPF), a progressive lung disease. About 320 participants will receive either rentosertib or a placebo daily for 52 weeks. The main …
Phase 3 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New pill shows promise in early trial for tough cancers
Disease control Recruiting nowThis early-stage trial is testing a new oral drug called ISM6331 in 100 adults with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug can shrink tumors. Partic…
Phase 1/2 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: first human trial of ISM3412 begins
Disease control Recruiting nowThis early-phase study tests a new drug called ISM3412 in people with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goals are to check the drug's safety and find the best dose. About 80 participants will take part in two stages: first to find…
Phase 1/2 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Could an AI-Designed pill take on Hard-to-Treat cancers?
Disease control Recruiting nowThis early-stage trial is testing an experimental oral drug called ISM8207 in people with advanced solid tumors or relapsed/refractory B-cell lymphoma who have no standard treatment options left. The main goals are to check the drug's safety, tolerability, and how the body proces…
Phase 1 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New pill aims to tame ulcerative colitis Flare-Ups
Disease control Recruiting nowThis study tests an experimental pill called ISM5411 (Garutadustat) in 80 adults with active ulcerative colitis. Half receive the drug, half a placebo, and neither patients nor doctors know who gets what. The goal is to check if the drug is safe and helps control the disease.
Phase 2 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New pill for scarred lungs enters human testing
Disease control Recruiting nowThis study tests an experimental oral drug called INS018_055 in 40 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing difficulty. The main goal is to check the drug's safety over 12 weeks. Participants will be randomly assigned to r…
Phase 2 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug ISM8969 enters first human safety tests
Knowledge-focused Recruiting nowThis Phase 1 trial is testing the safety and tolerability of a new drug called ISM8969 in healthy adults and obese adults at risk of heart disease. About 100 participants will receive either the drug or a placebo. The study aims to see how the body processes the drug and if it ca…
Phase 1 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC